

# Introduction to the Cholera Vaccine Session

Pablo Sanchez, MD

Chair, Cholera Vaccine Work Group

Advisory Committee on Immunization Practices

January 12, 2022

# Cholera vaccine work group members and contributors

## **ACIP members**

- Pablo Sanchez (chair)
- Matt Daley (member)

## ***Ex officio* members**

- Bill Alexander (NIH)
- Tina Mongeau (FDA)

## **CDC lead**

- Jenn Collins (NCEZID/DFWED)

## **ACIP liaisons**

- Carol Baker (IDSA)
- Elizabeth Barnett (ISTM)
- Adam Ratner (AAP)

## **Technical advisors**

- Mike Brady
- Ed Ryan (Harvard)
- Mary Wilson (UCSF/Harvard)

## **CDC contributors**

- Grace Appiah (NCEZID/DGMQ)
- Bruce Gutelius (NCEZID/DFWED)
- Eric Mintz (NCEZID/DFWED)
- Talia Pindyk (NCEZID/DFWED)
- John Su (NCEZID/DHQP)
- Farrell Tobolowsky (NCEZID/DFWED)

## **CDC GRADE consultants**

- Doug Campos-Outcalt
- Rebecca Morgan

# Policy topic under consideration by work group

- Should ACIP recommend CVD 103-HgR for children and adolescents aged 2–17 years traveling to an area with active cholera transmission?

# Today's agenda

- Vaxchora Vaccine – Pediatric Dose Development
  - James McCarty, MD (Stanford University, Emergent BioSolutions)
- Evidence to Recommendations: CVD 103-HgR among children and adolescents aged 2–17 years
  - Jennifer Collins, MD, MSc (CDC/NCEZID/DFWED)